Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Gilead Sciences Inc's Business Segments
Gilead Sciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
48
Largest Segment
Total product sales
Total Revenue
$ 6,960
Regions Reported
2
Revenue Share by Reportable Segment - FY
- Total product sales99.8%
- Total HIV72.3%
- Total product sales U S70.8%
- U S70.8%
- Total HIV U S57.5%
- Biktarvy48.3%
- Biktarvy U S37%
- Total Oncology11.6%
- Descovy11.6%
- Total Liver Disease11%
- Descovy U S10.9%
- Total Cell Therapy5.8%
- Total Oncology U S5.8%
- Trodelvy5.8%
- Total Liver Disease U S5.2%
- Yescarta4.8%
- Sofosbuvir Velpatasvir4.1%
- Genvoya3.8%
- Trodelvy U S3.6%
- Vemlidy3.4%
- Odefsey3.2%
- Genvoya U S3.1%
- Total Other2.8%
- Yeztugo2.4%
- Yeztugo U S2.3%
- Odefsey U S2.2%
- Total Cell Therapy U S2.2%
- Veklury2.1%
- Sofosbuvir Velpatasvir U S2%
- Symtuza - Revenue share2%
- AmBisome2%
- Livdelzi1.9%
- Yescarta U S1.7%
- Livdelzi U S1.7%
- Other Liver Disease1.6%
- Veklury U S1.6%
- Symtuza - Revenue share U S1.5%
- Vemlidy U S1.3%
- Tecartus1.1%
- Other HIV1%
- Other0.8%
- Total Other U S0.7%
- Other U S0.6%
- Other HIV U S0.5%
- Tecartus U S0.4%
- Other Liver Disease U S0.2%
- Royalty contract and other revenues0.2%
- AmBisome U S0.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Total product sales | $ 6,946 | 99.8% |
| Total HIV | $ 5,030 | 72.3% |
| Total product sales U S | $ 4,926 | 70.8% |
45 more segments available
Sign in to unlock the full Gilead Sciences Inc dataset.
Revenue Share by Region - FY
- Europe16.4%
- Rest of World12.8%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 1,144 | 16.4% |
| Rest of World | $ 889 | 12.8% |
Revenue by Product & Service Category - FY
- Product99.8%
- HIV Product Sales57.5%
- HIV Products, Biktarvy37%
- HIV Products, Descovy10.9%
- Oncology Product5.8%
- Liver Disease5.2%
- Trodelvy3.6%
- HIV Products, Genvoya3.1%
- HIV Products, Yeztugo2.3%
- HIV Products, Odefsey2.2%
- Cell Therapy Products, Total Cell Therapy Product Sales2.2%
- Liver Disease Products, Sofosbuvir/Velpatasvir2%
- Other Products, Yescarta1.7%
- Liver Disease Products, Livdelzi1.7%
- Veklury1.6%
- HIV Products, Symtuza - Revenue Share1.5%
- Liver Disease Products, Vemlidy1.3%
- Other Products, Total Other Product Sales0.7%
- Other Products, Other0.6%
- HIV Products, Other HIV0.5%
- Cell Therapy Products, Tecartus0.4%
- Liver Disease Products, Other Liver Disease0.2%
- Royalty, Contract, and Other0.2%
- Other Products, AmBisome0.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 6,946 | 99.8% |
| HIV Product Sales | $ 4,004 | 57.5% |
| HIV Products, Biktarvy | $ 2,573 | 37% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
21 more categories available
Sign in to unlock the full Gilead Sciences Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Total product sales99.8%
- Total HIV72.3%
- Total product sales U S70.8%
- U S70.8%
- Total HIV U S57.5%
- Biktarvy48.3%
- Biktarvy U S37%
- Total Oncology11.6%
- Descovy11.6%
- Total Liver Disease11%
- Descovy U S10.9%
- Total Cell Therapy5.8%
- Total Oncology U S5.8%
- Trodelvy5.8%
- Total Liver Disease U S5.2%
- Yescarta4.8%
- Sofosbuvir Velpatasvir4.1%
- Genvoya3.8%
- Trodelvy U S3.6%
- Vemlidy3.4%
- Odefsey3.2%
- Genvoya U S3.1%
- Total Other2.8%
- Yeztugo2.4%
- Yeztugo U S2.3%
- Odefsey U S2.2%
- Total Cell Therapy U S2.2%
- Veklury2.1%
- Sofosbuvir Velpatasvir U S2%
- Symtuza - Revenue share2%
- AmBisome2%
- Livdelzi1.9%
- Yescarta U S1.7%
- Livdelzi U S1.7%
- Other Liver Disease1.6%
- Veklury U S1.6%
- Symtuza - Revenue share U S1.5%
- Vemlidy U S1.3%
- Tecartus1.1%
- Other HIV1%
- Other0.8%
- Total Other U S0.7%
- Other U S0.6%
- Other HIV U S0.5%
- Tecartus U S0.4%
- Other Liver Disease U S0.2%
- Royalty contract and other revenues0.2%
- AmBisome U S0.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Total product sales | $ 6,946 | 99.8% |
| Total HIV | $ 5,030 | 72.3% |
| Total product sales U S | $ 4,926 | 70.8% |
45 more segments available
Sign in to unlock the full Gilead Sciences Inc dataset.
Description of Gilead Sciences Inc
Gilead Sciences, Inc. is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for patients with life-threatening diseases. Founded in 1987 and headquartered in Foster City, California, Gilead has established itself as a pioneer in the field of antiviral and anti-infective treatments, aiming to address some of the most pressing medical challenges globally.
The company’s extensive portfolio includes a diverse range of products primarily focused on the treatment of viral infections and other life-threatening conditions. Gilead has made significant advancements in the field of HIV/AIDS, with several antiretroviral therapies that have profoundly impacted patient care and quality of life. In addition to HIV treatments, Gilead has a strong presence in hepatology, particularly with therapies targeting hepatitis C and hepatitis B, which have played pivotal roles in the ongoing efforts to mitigate these diseases.
Gilead’s therapeutic focus extends to infectious diseases, particularly in the realms of antiviral and antifungal medications. The company has invested heavily in research and clinical trials to develop novel treatments for conditions such as influenza, respiratory viruses, and opportunistic infections in immunocompromised patients. With a commitment to scientific excellence, Gilead emphasizes the importance of innovation and has established robust research and development programs in order to expand its therapeutic offerings.
The company pursues growth through a multi-faceted approach that includes proprietary clinical development programs, collaborations with academic institutions, and an active strategy for product acquisition and in-licensing. This ensures that Gilead not only enriches its product pipeline but also enhances its capabilities in delivering new and effective therapeutic options to patients.
Gilead Sciences also places a strong emphasis on corporate social responsibility, working to improve access to its medicines in underserved populations worldwide. Through various initiatives, the company aims to bridge the gap in healthcare equity, ensuring that patients have access to life-saving treatments regardless of geographical or economic barriers.
In summary, Gilead Sciences, Inc. is at the forefront of biopharmaceutical innovation, committed to addressing serious health challenges through a focused portfolio of products and a relentless pursuit of scientific advancement. With a global presence and a dedication to patient care, Gilead continues to make strides in improving health outcomes and transforming the treatment of life-threatening diseases.
The company’s extensive portfolio includes a diverse range of products primarily focused on the treatment of viral infections and other life-threatening conditions. Gilead has made significant advancements in the field of HIV/AIDS, with several antiretroviral therapies that have profoundly impacted patient care and quality of life. In addition to HIV treatments, Gilead has a strong presence in hepatology, particularly with therapies targeting hepatitis C and hepatitis B, which have played pivotal roles in the ongoing efforts to mitigate these diseases.
Gilead’s therapeutic focus extends to infectious diseases, particularly in the realms of antiviral and antifungal medications. The company has invested heavily in research and clinical trials to develop novel treatments for conditions such as influenza, respiratory viruses, and opportunistic infections in immunocompromised patients. With a commitment to scientific excellence, Gilead emphasizes the importance of innovation and has established robust research and development programs in order to expand its therapeutic offerings.
The company pursues growth through a multi-faceted approach that includes proprietary clinical development programs, collaborations with academic institutions, and an active strategy for product acquisition and in-licensing. This ensures that Gilead not only enriches its product pipeline but also enhances its capabilities in delivering new and effective therapeutic options to patients.
Gilead Sciences also places a strong emphasis on corporate social responsibility, working to improve access to its medicines in underserved populations worldwide. Through various initiatives, the company aims to bridge the gap in healthcare equity, ensuring that patients have access to life-saving treatments regardless of geographical or economic barriers.
In summary, Gilead Sciences, Inc. is at the forefront of biopharmaceutical innovation, committed to addressing serious health challenges through a focused portfolio of products and a relentless pursuit of scientific advancement. With a global presence and a dedication to patient care, Gilead continues to make strides in improving health outcomes and transforming the treatment of life-threatening diseases.
Gilead Sciences, Inc. is a leading biopharmaceutical company known for its innovative approaches to treating various serious medical conditions, particularly in the areas of antiviral therapies, liver diseases, connective tissue diseases, and hematology. Its comprehensive portfolio is designed to address significant unmet medical needs with a strong emphasis on HIV/AIDS, hepatitis B and C, and other infectious diseases. Below is an extensive breakdown of the segments, products, and services offered by Gilead Sciences.
1. HIV Products
Viread (tenofovir disoproxil fumarate)
- Class: Nucleotide analogue reverse transcriptase inhibitor (NRTI)
- Indication: Utilized in combination therapy for the treatment of HIV infection in adults and adolescents.
- Formulation: Oral tablet, dosed once daily.
- Sales: Marketed globally, including the U.S. Europe, and Japan through various commercial teams and partners.
Emtriva (emtricitabine)
- Class: Nucleoside analogue reverse transcriptase inhibitor (NRTI)
- Indication: Used in combination therapy for treating HIV in adults.
- Formulation: Oral tablet, dosed once daily.
- Sales: Distributed via Gileads U.S. commercial team and in key European markets.
Truvada (emtricitabine and tenofovir disoproxil fumarate)
- Class: Fixed-dose combination of Emtriva and Viread.
- Indication: Approved for HIV treatment and indicated for pre-exposure prophylaxis (PrEP) to minimize the risk of acquiring HIV.
- Sales: Marketed globally, including in the U.S. and European Union.
Cabenuva (cabotegravir and rilpivirine)
- Class: Long-acting injectable therapy for HIV.
- Indication: Approved for adults who are virologically suppressed on a stable regimen.
- Administration: Administered as a monthly or every-two-month injection.
Antifungal and Antiviral Products
AmBisome (liposomal amphotericin B)
- Indication: Treatment of serious invasive fungal infections such as cryptococcal meningitis in patients with HIV/AIDS.
- Formulation: Proprietary liposomal formulation designed to reduce side effects, particularly nephrotoxicity.
- Global Sales: Approved in over 45 countries.
Hepsera (adefovir dipivoxil)
- Indication: Treatment of chronic hepatitis B in adults.
- Formulation: Oral tablet, dosed once daily.
- Sales: Marketed in the U.S. and select international markets, including a licensing agreement with GlaxoSmithKline (GSK) for specific territories.
Vistide (cidofovir)
- Indication: Treatment of cytomegalovirus (CMV) retinitis in AIDS patients.
- Sales: Available in the U.S. and in international markets through a partnership with Pfizer.
DaunoXome (liposomal daunorubicin)
- Indication: Treatment for AIDS-related Kaposis sarcoma.
- Sales: Approved in over 20 countries, Gilead continues to evaluate the product in select markets despite having reduced global sales efforts.
Other Therapeutics
Infectious Disease Treatments
- Tamiflu (oseltamivir): An antiviral medication for the prevention and treatment of influenza A and B. Developed through collaboration with Roche, Gilead receives royalties from Tamiflu sales.
Macugen (pegaptanib)
- Indication: Treatment of neovascular age-related macular degeneration (AMD).
- Sales Arrangement: Developed by Eyetech Pharmaceuticals, LLC, Gilead earns a share of the sales revenue.
Research and Development Focus
Gilead is deeply invested in research and development, concentrating on discovering new therapies for diseases that currently lack effective treatments. Priority areas include:
- Liver Diseases: Ongoing projects aim to address hepatitis B and C, with a focus on developing curative therapies.
- Hematology and Oncology: Gilead is exploring treatments for hematological malignancies, including potential therapies for leukemia and lymphoma.
- Infectious Diseases: Continued research on antiviral treatments to combat emerging infectious diseases beyond the current portfolio.
Commitment to Global Health
Gilead also actively participates in initiatives aimed at addressing global health challenges, including collaborations with governments, NGOs, and international organizations to improve access to essential medicines, particularly in resource-limited settings.
Conclusion
Gilead Sciences, Inc. has built a diverse and robust portfolio of products that address critical healthcare challenges, especially in the realms of HIV and viral infections. The company’s commitment to innovation through both internal research and strategic partnerships reflects its goal of improving patient outcomes and meeting the diverse needs of patient populations worldwide. With its ongoing focus on research and development and global health initiatives, Gilead aims to remain at the forefront of biopharmaceutical advancements.
1. HIV Products
Viread (tenofovir disoproxil fumarate)
- Class: Nucleotide analogue reverse transcriptase inhibitor (NRTI)
- Indication: Utilized in combination therapy for the treatment of HIV infection in adults and adolescents.
- Formulation: Oral tablet, dosed once daily.
- Sales: Marketed globally, including the U.S. Europe, and Japan through various commercial teams and partners.
Emtriva (emtricitabine)
- Class: Nucleoside analogue reverse transcriptase inhibitor (NRTI)
- Indication: Used in combination therapy for treating HIV in adults.
- Formulation: Oral tablet, dosed once daily.
- Sales: Distributed via Gileads U.S. commercial team and in key European markets.
Truvada (emtricitabine and tenofovir disoproxil fumarate)
- Class: Fixed-dose combination of Emtriva and Viread.
- Indication: Approved for HIV treatment and indicated for pre-exposure prophylaxis (PrEP) to minimize the risk of acquiring HIV.
- Sales: Marketed globally, including in the U.S. and European Union.
Cabenuva (cabotegravir and rilpivirine)
- Class: Long-acting injectable therapy for HIV.
- Indication: Approved for adults who are virologically suppressed on a stable regimen.
- Administration: Administered as a monthly or every-two-month injection.
Antifungal and Antiviral Products
AmBisome (liposomal amphotericin B)
- Indication: Treatment of serious invasive fungal infections such as cryptococcal meningitis in patients with HIV/AIDS.
- Formulation: Proprietary liposomal formulation designed to reduce side effects, particularly nephrotoxicity.
- Global Sales: Approved in over 45 countries.
Hepsera (adefovir dipivoxil)
- Indication: Treatment of chronic hepatitis B in adults.
- Formulation: Oral tablet, dosed once daily.
- Sales: Marketed in the U.S. and select international markets, including a licensing agreement with GlaxoSmithKline (GSK) for specific territories.
Vistide (cidofovir)
- Indication: Treatment of cytomegalovirus (CMV) retinitis in AIDS patients.
- Sales: Available in the U.S. and in international markets through a partnership with Pfizer.
DaunoXome (liposomal daunorubicin)
- Indication: Treatment for AIDS-related Kaposis sarcoma.
- Sales: Approved in over 20 countries, Gilead continues to evaluate the product in select markets despite having reduced global sales efforts.
Other Therapeutics
Infectious Disease Treatments
- Tamiflu (oseltamivir): An antiviral medication for the prevention and treatment of influenza A and B. Developed through collaboration with Roche, Gilead receives royalties from Tamiflu sales.
Macugen (pegaptanib)
- Indication: Treatment of neovascular age-related macular degeneration (AMD).
- Sales Arrangement: Developed by Eyetech Pharmaceuticals, LLC, Gilead earns a share of the sales revenue.
Research and Development Focus
Gilead is deeply invested in research and development, concentrating on discovering new therapies for diseases that currently lack effective treatments. Priority areas include:
- Liver Diseases: Ongoing projects aim to address hepatitis B and C, with a focus on developing curative therapies.
- Hematology and Oncology: Gilead is exploring treatments for hematological malignancies, including potential therapies for leukemia and lymphoma.
- Infectious Diseases: Continued research on antiviral treatments to combat emerging infectious diseases beyond the current portfolio.
Commitment to Global Health
Gilead also actively participates in initiatives aimed at addressing global health challenges, including collaborations with governments, NGOs, and international organizations to improve access to essential medicines, particularly in resource-limited settings.
Conclusion
Gilead Sciences, Inc. has built a diverse and robust portfolio of products that address critical healthcare challenges, especially in the realms of HIV and viral infections. The company’s commitment to innovation through both internal research and strategic partnerships reflects its goal of improving patient outcomes and meeting the diverse needs of patient populations worldwide. With its ongoing focus on research and development and global health initiatives, Gilead aims to remain at the forefront of biopharmaceutical advancements.